ArticleActa pharmacologica Sinica2020

Isosibiricin inhibits microglial activation by targeting the dopamine D1/D2 receptor-dependent NLRP3/caspase-1 inflammasome pathway.

Yan-Hang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.